Emergent BioSolutions (EBS) Tops Q4 EPS by 8c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.18 +0.49%
Revenue Growth %: +32.0%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
CCEL, SLP, TMQ, More
Revenue Growth %: +32.0%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $0.78, $0.08 better than the analyst estimate of $0.70. Revenue for the quarter came in at $168.1 million versus the consensus estimate of $168.07 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Key things to know ahead of SK Hynix’s blockbuster US listing
- JPMorgan Upgrades ArcelorMittal (MT:NA) (MT) to Neutral
- JPMorgan Downgrades PhysicsWallah Ltd (PWL:IN) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
